Latest

Samsara Expands Agentic AI and Connected Operations Tools Across Europe Samsara (NYSE: IOT) introduced a new suite of AI-powered operations

Samsara (NYSE: IOT) introduced a new suite of AI-powered operations tools for European customers, led by Agent Studio, a no-code platform that allows companies...

11-18-26

L3Harris Demonstrates AI-Enabled Multi-Domain Defense Capabilities in Taiwan L3Harris Technologies (NYSE: LHX) and industry partners demonstrated AI-enhanced multi-domain defense capabilities

L3Harris Technologies (NYSE: LHX) and industry partners demonstrated AI-enhanced multi-domain defense capabilities during its EVEREST: Pacific Vigilance exercise in Taiwan. The event showcased interoperable...

11-18-26

Aon and Swiss Re Launch Digital Claims Connectivity Through Claims Copilot Aon (NYSE: AON) and Swiss Re Corporate Solutions launched

Aon (NYSE: AON) and Swiss Re Corporate Solutions launched a digital claims connection designed to speed up claims processing and reduce administrative work between...

11-18-26

Regeneron Wins EU Approval for More Flexible Libtayo Dosing Across Multiple Cancers Regeneron Pharmaceuticals (NASDAQ: REGN) said the European Commission

Regeneron Pharmaceuticals (NASDAQ: REGN) said the European Commission approved a more flexible dosing schedule for Libtayo across all six of its approved skin, lung...

11-18-26

BlackRock to Acquire SulAmérica Investimentos, Expanding Brazil Asset Management Presence BlackRock (NYSE: BLK) entered into a definitive agreement to acquire

BlackRock (NYSE: BLK) entered into a definitive agreement to acquire SulAmérica Investimentos, a Brazilian asset manager with approximately $17 billion in assets under management....

11-18-26

Accenture Life Trends 2027 Highlights Consumer Pushback Against AI Sameness Accenture (NYSE: ACN) released its Life Trends 2027 report, finding

Accenture (NYSE: ACN) released its Life Trends 2027 report, finding that consumers broadly support technological progress but increasingly want more control over how AI,...

11-18-26

Workday to Acquire Honeydew to Strengthen AI Data Governance and Business Intelligence Workday (NASDAQ: WDAY) announced plans to acquire Honeydew,

Workday (NASDAQ: WDAY) announced plans to acquire Honeydew, a semantic-layer technology company focused on providing consistent, governed business definitions across AI agents and business...

11-18-26

Rockwell Automation to Acquire AGILOX, More Than Doubling Its Autonomous Mobile Robot Business Rockwell Automation (NYSE: ROK) signed a definitive

Rockwell Automation (NYSE: ROK) signed a definitive agreement to acquire Austria-based AGILOX, expanding its autonomous mobile robot portfolio and accelerating its physical AI strategy....

11-18-26

Baird Cuts Qualcomm Price Target to $300, Maintains Outperform Rating Robert W. Baird lowered its price target on Qualcomm (NASDAQ:

Robert W. Baird lowered its price target on Qualcomm (NASDAQ: QCOM) to $300 from $320 while maintaining an Outperform rating. Analyst Tristan Gerra issued...

11-18-26

Citigroup Downgrades New York Times to Neutral and Cuts Price Target to $76 Citigroup downgraded The New York Times Company

Citigroup downgraded The New York Times Company (NYSE: NYT) to Neutral from Buy and lowered its price target to $76 from $85. Analyst Jason...

11-18-26

JPMorgan Cuts Futu Price Target to $103, Maintains Neutral Rating JPMorgan lowered its price target on Futu Holdings (NASDAQ: FUTU)

JPMorgan lowered its price target on Futu Holdings (NASDAQ: FUTU) to $103 from $122 while maintaining a Neutral rating on the stock. Analyst Katherine...

11-18-26

Erste Group Downgrades Freeport-McMoRan to Hold Erste Group Bank downgraded Freeport-McMoRan (NYSE: FCX) to Hold from Buy. Freeport-McMoRan shares were

Erste Group Bank downgraded Freeport-McMoRan (NYSE: FCX) to Hold from Buy. Freeport-McMoRan shares were trading at $50.99, down 7.8% on the day. The downgrade...

11-18-26

NASDAQ:NVDA

Post Image
NVIDIA Rises 3% Premarket as Q3 Revenue Doubles and Vera Rubin Ramp Accelerates

NVIDIA (NASDAQ: NVDA) shares rose 3% in premarket trading after the company reported another quarter of exceptional AI-driven growth, with third-quarter revenue reaching $115.8 billion, up 103% year over year and 20% sequentially.

Data Center revenue climbed 110% year over year to $107.6 billion, while non-GAAP operating income more than doubled to $77.9 billion. Non-GAAP diluted EPS rose 111% to $2.68, and non-GAAP gross margin remained strong at 74.9%.

The company also began shipping Vera Rubin NVL72, describing it as the fastest product ramp in NVIDIA’s history, with deployments underway across major cloud providers including Google Cloud, Microsoft Azure, Oracle Cloud Infrastructure and CoreWeave. NVIDIA also highlighted broad adoption of Vera Rubin, Vera CPUs, networking and AI infrastructure across hyperscalers, AI labs and enterprise partners.

For the fourth quarter, NVIDIA expects revenue of about $130 billion, plus or minus 3%, while assuming no Data Center compute revenue from China. The premarket gain appears to reflect continued triple-digit Data Center growth, a strong Vera Rubin ramp and another step-up in quarterly revenue despite some expected gross-margin moderation.
Post Image
NVIDIA Creates Board Committee for National Security and Export Controls

NVIDIA (NASDAQ: NVDA) established a new board-level National Security and Export Control Oversight Committee to oversee the company’s national security policies, export control compliance and global trade risk management.

The committee will be chaired by director Suzanne Nora Johnson and will also include Stephen C. Neal and John O. Dabiri. NVIDIA’s National Security Team and Global Trade Compliance Team will report directly to the committee and to Interim CEO Colette Kress on day-to-day operations.

The committee will meet at least quarterly and use independent outside experts in law, national security and trade compliance.

The move strengthens NVIDIA’s governance around increasingly sensitive advanced-computing technologies and export controls, reflecting the company’s growing exposure to geopolitical and national-security scrutiny.
Post Image
IBM, Fermilab and NVIDIA Plan New Modular Quantum Computing Platform

IBM (NYSE: IBM), Fermilab and NVIDIA announced plans to develop a new co-design platform combining IBM quantum systems with NVIDIA DGX B200 infrastructure to advance modular, fault-tolerant quantum computing.

The collaboration will also integrate quantum processors more directly into Slurm through the vendor-neutral QRMI interface, allowing HPC centers to schedule QPUs alongside CPUs and GPUs using familiar workflows.

Separately, IBM, RIKEN and NVIDIA reported a quantum-classical simulation that achieved a 79-fold improvement in accuracy over earlier runs while studying a complex iron-sulfur molecule.

The initiative strengthens IBM’s strategy of embedding quantum computing more deeply into conventional supercomputing environments while developing architectures for larger future quantum systems.
Post Image
NVIDIA Expands Slurm Support to Integrate Quantum Processors Into Supercomputing

NVIDIA (NASDAQ: NVDA) announced an expansion of Slurm aimed at making quantum processors easier to integrate into traditional supercomputing environments, extending the company’s push into hybrid quantum-classical computing.

The new Slurm release allows quantum processing unit developers to create a standardized interface to their hardware that can be reused across supercomputing centers. The system builds on the QRMI and QDMI interfaces and is already being adopted by Alice & Bob, IBM, IQM, Pasqal, Quantinuum and MQSC.

Slurm 26.11 is expected to become available later in November.

The development addresses a major integration bottleneck in quantum computing. Previously, connecting a new QPU to a supercomputing center often required custom software work for each combination of hardware and facility. The expanded Slurm architecture is designed to let centers incorporate quantum processors into existing workload scheduling and resource-management systems.

NVIDIA said scientists will also be able to run hybrid applications developed with CUDA-Q while Slurm coordinates access to CPUs, GPUs and quantum processors.

The company simultaneously expanded its broader quantum-GPU platform at SC26. New capabilities include CUDA-Q QEC for quantum error-correction research, CUDA-Q Algorithms for reusable quantum application components and CUDA-Q Pulse for GPU-accelerated qubit control.

NVIDIA highlighted several early performance demonstrations, including Fermilab using CUDA-Q to complete studies in three weeks that would otherwise have taken five months. QunaSys also used 1,024 NVIDIA Hopper GPUs to simulate more than 300 million quantum operations, while NVIDIA researchers simulated 104 qubits under realistic noise conditions on the JUPITER supercomputer.

The announcement strengthens NVIDIA’s position as an infrastructure and software provider connecting classical accelerated computing with emerging quantum systems, rather than relying on any single quantum hardware architecture.

Nvidia CEO Huang resigns amid affair scandals, board names CFO Colette Kress interim CEO

Nvidia CEO Jensen Huang is resigning following reports that he had an affair with a fellow executive at the AI giant and after he admitted to having a separate affair with a woman who US intelligence officials believe is a Chinese spy.

(finance.yahoo.com)

Nvidia live updates: Jensen Huang resigns, CFO Colette Kress to serve as interim CEO

Follow along for live updates and reactions to reports of Nvidia CEO Jensen Huang's involvement in two extramarital affairs and exit from the company.

(finance.yahoo.com)

Nvidia reportedly preparing to oust CEO Huang after alleged affairs with spy, Nvidia exec

Embattled Nvidia (NVDA) CEO Jensen Huang was allegedly involved in a second extramarital affair.

(finance.yahoo.com)
Post Image
NVIDIA Expands Korea AI Strategy With Investments in Point2, Motif, RLWRLD and Upstage

NVIDIA announced new planned investments in Korean artificial intelligence startups, expanding its exposure across AI infrastructure, foundation models, enterprise software and robotics.

The company confirmed an investment in Point2 Technology and said additional investments are planned in Motif Technologies, RLWRLD and Upstage. The announcement came during the MSIT-NVIDIA AI Startup Partnership Forum in Seoul, hosted with Korea’s Ministry of Science and ICT.

Point2 develops radio-frequency interconnect technology designed to move data between chips and racks in AI factories, offering an alternative to conventional copper and optical connections. Motif Technologies develops foundation models for AI agents, while RLWRLD is building robotics foundation models for humanoid and industrial robots performing complex physical tasks.

Upstage focuses on enterprise AI, including its Solar language models and document AI tools for extracting information and automating business workflows.

The investments broaden NVIDIA’s engagement across the full AI stack, from data-center infrastructure to software and physical AI. They also deepen the company’s relationship with Korea’s technology ecosystem, where more than 1,000 startups already participate in the NVIDIA Inception program.

The initiative reinforces NVIDIA’s strategy of supporting companies that could expand demand for AI computing infrastructure while accelerating development of agentic AI, robotics and next-generation AI factories.
Post Image
NVIDIA Says Vera CPU Delivers Faster AI Agent Performance With Higher Energy Efficiency

NVIDIA (NASDAQ: NVDA) said its Vera CPU can improve both AI agent performance and energy efficiency, targeting data centers increasingly constrained by power availability as agentic AI workloads expand.

According to NVIDIA, Vera enables 1.6 times more AI agents per watt than the fastest x86 CPU while delivering industry-leading agent speed. Compared with the most energy-efficient x86 processor tested, Vera delivered roughly twice the agent speed while maintaining strong power efficiency.

The company highlighted early performance results from several partners. Perplexity reported agentic coding workloads running 1.5 times faster on Vera than traditional CPUs, while DeepInfra achieved up to 2.2 times the speed of its best x86 processor in agent orchestration workloads.

Other tests showed ClickHouse scaling nearly linearly across 176 cores, while Daytona brought 1,000 AI-agent sandboxes online in 10.8 seconds compared with 88.4 seconds using x86 infrastructure. Modal reported up to twice the sandbox throughput per core.

The results reinforce NVIDIA’s push beyond GPUs into CPUs and full-stack AI infrastructure, as data center operators increasingly seek to maximize AI workloads per watt while supporting growing numbers of autonomous agents.
Post Image
NVIDIA will host a conference call on Tuesday, November 17, at 5 p.m. ET to discuss its financial results for the third quarter of fiscal year 2027, which ended October 25, 2026.
Video Thumbnail
11-18-26WS News
Video Thumbnail
11-18-26WS News
Video Thumbnail
11-17-26The Investor
Video Thumbnail
11-17-26The Investor
Video Thumbnail
11-16-26WS News

US

Post Image
Atlanta Fed GDPNow Estimate Slips to 3.2% for Q4

The Atlanta Fed’s GDPNow estimate for U.S. fourth-quarter economic growth fell to 3.2%, down from the previous 3.4% estimate and below the 3.4% consensus reading.

The revision still points to a solid pace of economic expansion, but it suggests slightly weaker momentum than previously estimated.
U.S. Housing Starts Rebound Sharply in October but Building Permits Disappoint

U.S. housing starts jumped 9.9% month over month in October, far above the 2.4% consensus estimate and reversing the previous month’s 7.0% decline.

The annualized pace of housing starts rose to 1.309 million, beating expectations of 1.250 million and up from 1.191 million previously.

Building permits were weaker, however, falling to 1.295 million compared with the 1.380 million forecast and 1.398 million in the prior month.

The data point to a strong rebound in current residential construction activity, but the softer permits figure suggests momentum may be less robust in the months ahead.
Post Image
U.S. Retail Sales Beat Forecasts While Industrial Production Falls

U.S. retail sales rose 0.2% month over month in October, above the 0.1% forecast but slowing sharply from the previous 0.8% increase. Core retail sales were stronger, rising 0.6% versus the 0.4% forecast, although also below the prior 1.1% gain.

Weekly ADP employment growth accelerated to 23,800 jobs from 19,800 previously, suggesting continued resilience in private-sector hiring.

Industrial production provided a weaker signal, falling 0.4% month over month compared with expectations for no change and a previous 0.7% increase. On an annual basis, production was up 2.15%, little changed from 2.14%.

Meanwhile, the Atlanta Fed’s GDPNow estimate for fourth-quarter growth edged down to 3.4% from 3.5%, pointing to still-solid economic momentum despite softer industrial activity.
Post Image
New York Manufacturing Index Falls to 7.8 in November, Missing Expectations

The New York Empire State Manufacturing Index fell to 7.8 in November, well below the 17.6 forecast.

The reading also declined sharply from 25.5 in the previous month, indicating a significant slowdown in manufacturing activity across New York state.

The index remained above zero, which still signals expansion, but the drop suggests growth momentum weakened considerably during the month.
Post Image
U.S. Stocks Fall as Nasdaq Drops 1.5% and S&P 500 Slides Nearly 1%

U.S. stocks traded lower, with technology shares leading the decline as the Nasdaq Composite fell 1.54% to 24,974.47.

The S&P 500 dropped 0.97% to 7,518.86, while the Dow Jones Industrial Average declined 0.45% to 52,059.91.

The sharper Nasdaq decline points to heavier selling pressure in technology and other growth-oriented stocks, while the Dow’s smaller loss suggests relative resilience among large-cap industrial and value names.

The broad weakness comes as investors reassess the outlook for interest rates, Nvidia scandal and inflation following fresh U.S. economic data, contributing to a more cautious tone across equity markets.
Post Image
U.S. Producer Prices Rise 0.3% in October, Below Headline Forecast

U.S. producer prices increased 0.3% month over month in October, slightly below the 0.4% forecast and sharply slower than the previous 1.4% increase.

Core producer prices, which exclude food and energy, also rose 0.3% during the month, matching expectations and easing from the prior 0.8% increase.

The data suggest upstream inflation pressures moderated significantly in October after the unusually strong rise in the previous month.
Post Image
S&P 500 Edges Higher as Energy and Communication Services Lead Gains

The S&P 500 was modestly higher in midday trading, rising about 0.17% to 7,632.36 as strength in energy and communication services offset weakness in technology and materials.

Energy was the strongest-performing sector, gaining 1.83%, followed by communication services at 1.00%. Utilities rose 0.64%, consumer staples gained 0.49%, consumer discretionary advanced 0.38% and health care added 0.36%.

The broader market initially traded lower after the open before rebounding sharply during the late morning session. The S&P 500 briefly approached the 7,650 level before giving back part of its gains and stabilizing near 7,630 around midday.

Defensive and cyclical sectors generally outperformed technology. Real estate slipped 0.02%, financials fell 0.04% and industrials declined 0.06%. Information technology was down 0.32%, while materials was the weakest sector with a 0.49% decline.

The mixed sector performance suggests investors were rotating away from some technology and materials names while maintaining exposure to energy, communication services and defensive sectors.

With the S&P 500 holding slightly positive despite weakness in several major sectors, the session reflects a relatively balanced market rather than a broad-based risk-on move.
Post Image
U.S. Existing Home Sales Fall 5.5% in October, Missing Expectations

U.S. existing home sales fell sharply in October, declining 5.5% month over month compared with expectations for a 3.5% decrease.

The annualized sales rate dropped to 3.75 million units, below the 3.89 million forecast and down from 3.97 million in the previous month.

The weaker-than-expected figures point to renewed pressure in the U.S. housing market after sales had increased 1.0% in the prior month.

The data suggest elevated borrowing costs and affordability constraints continue to weigh on housing demand, adding another sign of softness in interest-rate-sensitive parts of the U.S. economy.
Post Image
U.S. Initial Jobless Claims Rise to 200,000 While Continuing Claims Decline

U.S. initial jobless claims rose to 200,000, above the 194,000 market forecast and up from 191,000 in the previous week.

The increase suggests a modest rise in new unemployment claims, although the overall level remains relatively low.

Continuing jobless claims, meanwhile, fell to 1.697 million from 1.717 million, coming in below expectations of 1.710 million.

The mixed data point to some softening in new claims but continued resilience among those already receiving unemployment benefits, leaving the broader U.S. labor-market picture relatively stable.
Post Image
U.S. CPI Rises More Than Expected in October as Core Inflation Holds at 0.3%

U.S. consumer prices rose 0.4% month over month in October, above the 0.3% forecast but slowing from September’s 0.6% increase.

Core CPI, which excludes food and energy, increased 0.3%, also exceeding the 0.2% forecast and matching the previous month’s pace.

Separately, ADP’s weekly employment measure showed private payrolls increasing by 19,800, slightly above the previous reading of 19,500.

U.S. equities traded modestly lower following the data. The S&P 500 was down 0.19%, the Dow Jones Industrial Average fell 0.35%, and the Nasdaq declined 0.06%.

The hotter-than-expected headline and core CPI readings suggest underlying inflation pressures remain persistent, potentially reinforcing expectations that the Federal Reserve will remain cautious about further monetary-policy easing.
Video Thumbnail
11-18-26WS News
Video Thumbnail
11-16-26WS News
Video Thumbnail
11-15-26WS News
Video Thumbnail
11-13-26Global Finance News
Video Thumbnail
11-08-26WS News

NYSE:MS

Morgan Stanley Launches Active ETF Platform in Europe

Morgan Stanley Investment Management has launched its first active ETF platform in Europe, introducing four Ireland-domiciled UCITS ETFs across major European markets including Germany, Italy, Switzerland and the U.K.

The initial lineup consists of four distinct active equity strategies: a global AI and technology diffusion strategy, a global future-of-energy strategy, a global strategy focused on opportunities arising from an increasingly multipolar world, and a dedicated European equities strategy. The funds combine bottom-up fundamental research with systematic analysis incorporating insights from Morgan Stanley Research.

The expansion builds on Morgan Stanley’s U.S. ETF business, launched in 2023, which had grown to more than $18.5 billion in assets across 21 products as of October 31, 2026.

The launch is strategically positive for Morgan Stanley (NYSE: MS), giving its investment-management business another avenue to capture European fund flows and expand fee-generating assets. While the near-term financial impact is likely limited, the platform creates a foundation for broader ETF growth in a market where investor demand for active strategies is increasing.
Morgan Stanley Launches Active ETF Platform in Europe

Morgan Stanley Investment Management has launched its first active ETF platform in Europe, introducing four Ireland-domiciled UCITS ETFs across markets including Germany, Italy, Switzerland and the U.K.

The initial lineup includes three global strategies focused on AI and technology diffusion, the future of energy, and the shift toward a multipolar world, alongside a fourth strategy dedicated to European equities. The funds combine bottom-up fundamental research with systematic analysis incorporating insights from Morgan Stanley Research.

The European expansion builds on Morgan Stanley’s U.S. ETF business, which launched in 2023 and had grown to more than $18.5 billion in assets across 21 products as of October 31, 2026.

The move broadens Morgan Stanley’s European investment-management offering as demand for active ETFs continues to grow, while giving the firm a platform for further product expansion across the region.
Post Image
Morgan Stanley to Acquire Vinyl Equity, Expanding Private-to-Public Market Infrastructure

Morgan Stanley (NYSE: MS) agreed to acquire Vinyl Equity, a digital-first SEC-registered transfer agent, expanding its Morgan Stanley at Work platform with shareholder recordkeeping and transfer-agency capabilities.

The transaction will connect cap table management, equity administration, share transfer and wealth management infrastructure across private and public markets. Morgan Stanley said the combination is intended to give companies a more integrated platform as they move through IPOs, liquidity events and other private-to-public transitions.

Founded in 2022, Vinyl has built a digital-native transfer-agent platform designed to replace historically manual processes with digital workflows, real-time reporting and streamlined administration. Its services include shareholder recordkeeping, proxy administration, corporate actions management and paying agency solutions.

Morgan Stanley also highlighted Vinyl’s strategic importance for future digital-asset infrastructure. The firm said the acquisition will support work around blockchain technology, atomic settlement and tokenization by strengthening the systems used to record and transfer ownership.

The deal builds on Morgan Stanley’s broader private-markets ecosystem, which includes EquityZen, its Private Markets Transaction Desk and its collaboration with Carta. Morgan Stanley at Work currently serves more than 3,400 corporate clients and 6.7 million participants, including roughly half of the S&P 500 and more than 70% of the top 100 unicorns by market capitalization.

The acquisition is expected to close in the first quarter of 2027, subject to customary closing conditions. Financial terms were not disclosed.
Post Image
Morgan Stanley Falls 3.3% as Higher Expenses and Fixed Income Weakness Offset Strong Equities and Wealth Growth

Morgan Stanley (NYSE: MS) shares fell about 3.3% after the bank reported third-quarter 2026 net revenues of $20.3 billion and net income of $4.9 billion, or $3.03 per diluted share. Revenue rose from $18.2 billion a year earlier, while EPS increased from $2.80.

Institutional Securities delivered strong growth, with revenue increasing to $10.0 billion from $8.5 billion. Equity revenue surged 41% to $5.8 billion, supported by broad client activity and strength in Asia. Investment Banking revenue rose 2%, helped by stronger advisory revenue, while Fixed Income revenue declined 7% to $2.0 billion.

Wealth Management was another bright spot, posting record revenue of $9.1 billion and a pre-tax margin of 30.4%. The business attracted a record $232 billion of net new assets and $80 billion of fee-based flows during the quarter.

Investment Management was weaker, with revenue falling 12% to $1.46 billion and pre-tax income declining to $259 million. The decline reflected a reversal of accrued carried interest tied mainly to investments in one private fund.

Expenses also increased meaningfully. Firmwide compensation expense rose to $8.0 billion from $7.4 billion, while non-compensation expense climbed to $5.7 billion from $4.8 billion. The expense efficiency ratio remained at 67%, while ROTCE declined to 22.6% from 23.5% a year earlier.

The 3.3% decline therefore appears to reflect investor concern over higher expenses, weaker Fixed Income and Investment Management performance, and lower year-over-year ROTCE, despite strong equity trading, record Wealth Management revenue and substantial client asset inflows.
Morgan Stanley Plans to Convert Nearly $10 Billion of Municipal Mutual Funds Into ETFs

Morgan Stanley (NYSE: MS) announced plans to convert eight municipal bond mutual funds representing nearly $10 billion in assets into seven newly created ETFs and one existing ETF, significantly expanding its presence in the fast-growing actively managed ETF market. The proposed conversions remain subject to shareholder approval and other closing conditions.

The initiative reflects growing investor demand for actively managed municipal bond ETFs, which combine professional portfolio management with the liquidity, transparency and accessibility of the ETF structure. The proposed products would give Morgan Stanley Investment Management exposure across different municipal bond maturities, income profiles and credit segments.

Morgan Stanley has already seen significant growth from earlier mutual-fund conversions. The Eaton Vance Total Return Bond ETF has expanded from $363 million at its March 2024 conversion to more than $6 billion, while the Eaton Vance Short Duration Municipal Income ETF has more than tripled its assets.

The move would further scale Morgan Stanley’s ETF business, which has grown to more than $16 billion in assets across 22 ETF and ETP products since launching in 2023. The broader investment-management operation oversees or manages approximately $2 trillion in assets.
Morgan Stanley Stock Rises as Goldman Sachs Raises Price Target to $233

Morgan Stanley (NYSE: MS) climbed more than 3% on Monday after Goldman Sachs maintained its Neutral rating while raising its price target on the investment bank to $233 from $211.

The higher price target reflects improving expectations for Morgan Stanley's earnings outlook as investment banking activity and capital markets continue to recover. A stronger environment for equity offerings, mergers and acquisitions, and debt issuance has fueled optimism for fee income across major Wall Street banks.

Morgan Stanley also remains well positioned to benefit from resilient wealth management operations, which continue to provide stable recurring revenue alongside improving institutional securities performance. Higher client activity and a favorable backdrop for financial markets have further supported investor sentiment toward the banking sector.

Although Goldman Sachs kept its Neutral rating, the higher valuation target signaled increased confidence in Morgan Stanley's long-term earnings potential, helping lift shares during Monday's session.

The move comes as financial stocks continue to attract investor interest amid expectations of improving capital markets activity and a resilient U.S. economy, with investors now looking ahead to the upcoming earnings season for further insight into the sector's performance.
Morgan Stanley reported strong third-quarter 2025 results, posting net revenues of $18.2 billion, up from $15.4 billion a year earlier, and earnings per share of $2.80. Net income rose to $4.6 billion, delivering a return on tangible common equity (ROTCE) of 23.5%, reflecting strength across all business divisions.

CEO Ted Pick highlighted “record revenues” and “consistent execution” across the firm’s integrated businesses. Wealth Management generated record revenue of $8.2 billion with $81 billion in net new assets, while Institutional Securities revenue surged to $8.5 billion, supported by a rebound in investment banking and strong equity trading. Investment Management also grew, with revenue reaching $1.7 billion and long-term net inflows of $16.5 billion.
Morgan Stanley Posts Strong Q2 2025 Results with $3.5 Billion Profit

Morgan Stanley reported second-quarter 2025 net revenues of $16.8 billion, up from $15.0 billion a year earlier. Net income reached $3.5 billion, or $2.13 per diluted share, compared to $3.1 billion and $1.82 per share in Q2 2024. Return on tangible common equity (ROTCE) was 18.2%, reflecting continued earnings strength.
Lynn Good Elected to Morgan Stanley Board of Directors

Morgan Stanley announced the election of Lynn Good to its Board of Directors, effective July 18, 2025. Good is the former Chair, CEO, and President of Duke Energy and brings extensive executive leadership and financial oversight experience.

Upon her appointment, the Board will expand to 15 members. Good will also serve on the Audit Committee.

Chairman and CEO Ted Pick highlighted her strategic insight and expertise in accounting and financial reporting, emphasizing the value she brings to the firm's leadership. Ray Wilkins, Chair of the Governance and Sustainability Committee, also expressed confidence in her contributions to the Board’s work.
Morgan Stanley Projects Deal Rebound, Highlights Strong IPO Pipeline

NEW YORK — June 10, 2025 — Morgan Stanley signaled renewed momentum in investment banking activity during a recent investor presentation, citing a recovery in equity capital markets and a robust pipeline of initial public offerings (IPOs).

Chief Executive Officer Ted Pick stated that deal volumes showed improvement following a temporary slowdown in April and early May. The firm is currently advising several high-profile IPOs, including digital bank Chime, musculoskeletal health firm Hinge Health, and adtech platform MNTN, with combined proceeds estimated above $1.4 billion.

Beyond equity markets, Morgan Stanley is leading major M&A transactions, such as Motorola’s $5 billion acquisition of Silvus Technologies and AT&T’s $5.75 billion purchase of Lumen Technologies’ consumer fiber division. Pick noted that upcoming regulatory adjustments could open the door to strategic acquisitions, particularly as leverage ratio frameworks evolve.

The firm also emphasized cost discipline, having recently completed a 3% workforce reduction affecting approximately 2,000 positions. Leadership stated the move was part of an effort to align resources with long-term growth and profitability targets.

Looking ahead, Morgan Stanley reaffirmed its strategic focus on expanding its wealth and investment management businesses while continuing to capitalize on cyclical improvements in advisory and underwriting markets.
Video Thumbnail
06-10-26WS Investor
Video Thumbnail
04-15-26WS News
Video Thumbnail
10-29-25The Investor
Video Thumbnail
10-15-25European Investor
Video Thumbnail
10-03-25WS News

Canada

Canada New Housing Prices Fall 0.2% in October

Canada’s New Housing Price Index fell 0.2% month over month in October, weaker than the 0.1% increase expected by economists.

The decline matched the previous month’s 0.2% decrease, indicating continued softness in new-home pricing.

The weaker-than-expected reading suggests housing price pressures remain subdued, adding to signs of a softer residential property market.
Canada Housing Starts Beat Forecasts in October

Canadian housing starts came in at an annualized 244,600 units in October, above the 241,000 forecast.

The reading was still below the previous month’s 250,100 pace, indicating a modest slowdown from September despite outperforming expectations.
Post Image
Canada Core Inflation Accelerates in October While Headline CPI Rises Less Than Expected

Canada’s core consumer price index rose 0.4% month over month in October, above the 0.2% forecast and up from a flat reading in the previous month.

On an annual basis, core CPI eased to 2.0% from 2.2%, indicating that underlying inflation moderated compared with a year earlier despite the stronger monthly increase.

Headline CPI rose 0.2% month over month, below expectations for a 0.3% increase but slightly above the previous 0.1% gain.

Overall, the data present a mixed inflation picture, with stronger monthly core price pressures offset by softer headline inflation and a lower annual core rate.
Post Image
Canada Wholesale Sales Rise 0.7% in September, Beating Expectations

Canadian wholesale sales increased 0.7% month over month in September, exceeding expectations for a 0.5% gain.

The result also marked a clear rebound from the previous month’s 1.4% decline.

The stronger-than-expected increase suggests wholesale activity improved heading into the fourth quarter, pointing to firmer underlying demand across the distribution sector.
Post Image
Canada Building Permits Fall 4.1% in September, Slightly Worse Than Expected

Canadian building permits fell 4.1% month over month in September, slightly worse than the 4.0% decline expected by economists and reversing the previous month’s 7.6% increase.
Post Image
Canada Trade Surplus Widens to C$5.35 Billion in September, Beating Forecasts

Canada’s trade surplus widened to C$5.35 billion in September, exceeding the C$4.80 billion forecast and improving from C$4.95 billion in the previous month.

The stronger-than-expected result points to a more favorable external trade position and suggests that exports continued to provide support to the Canadian economy during the month.
Canada Inflation Cools in September as Core CPI Slows

Canada’s core inflation eased in September, with Core CPI rising 2.2% year over year, down from 2.4% previously.

On a monthly basis, Core CPI was unchanged at 0.0%, compared with a 0.1% increase in the prior month, signaling softer underlying price pressure.

Headline CPI increased 0.1% month over month, below the 0.2% consensus estimate but rebounding from a 0.1% decline previously.

Overall, the data point to a moderation in Canadian inflation pressures. Softer core inflation and a below-consensus monthly headline reading could strengthen expectations that the Bank of Canada has more room to maintain or pursue a less restrictive monetary policy stance, depending on labor-market and broader economic conditions.
Post Image
Canada Wholesale Sales Fall 1.6% in August, Slightly Worse Than Expected

Canadian wholesale sales declined 1.6% month over month in August, slightly weaker than the 1.5% contraction expected by economists.
The drop also marked a reversal from the previous month’s 0.4% increase, pointing to softer activity in the wholesale sector.

The result suggests some loss of momentum in goods distribution and business demand heading into the end of the third quarter.
Post Image
Canada Building Permits Jump 8.8% in August, Beating Expectations

Canadian building permits rose 8.8% month over month in August, significantly above the 2.9% increase expected by economists.

The gain marked a sharp rebound from the previous month’s 15.8% decline, suggesting renewed momentum in planned construction activity after a weak July.
Post Image
Canada Employment Falls Sharply in September as Unemployment Holds at 6.5%

Canada lost 68,300 jobs in September, a much weaker result than the 6,100 increase expected by economists and following a 41,700 decline previously.

Despite the sharp drop in employment, the unemployment rate held at 6.5%, matching expectations but edging up from 6.4% in the prior month.

The data point to continued weakness in the Canadian labor market. Two consecutive months of sizable employment losses suggest hiring momentum has deteriorated, even though the unemployment rate has not yet moved materially higher.
Video Thumbnail
10-06-26Global Finance News
Video Thumbnail
09-17-26WS News
Video Thumbnail
09-09-26European Investor
Video Thumbnail
09-07-26WS News
Video Thumbnail
08-24-26The Investor

NASDAQ:GILD

Gilead Expands Ebola Access Strategy Through Voluntary Licensing

Gilead Sciences (NASDAQ: GILD) signed royalty-free voluntary licensing agreements with Dr. Reddy’s Laboratories, Eva Pharma and Ferozsons Laboratories to support potential future access to investigational obeldesivir for Ebola Bundibugyo virus disease.

The agreements cover 127 primarily low- and lower-middle-income countries and are intended to support manufacturing readiness, technology transfer and supply planning while the Phase 3 EBO-PEP trial evaluates obeldesivir as post-exposure prophylaxis.

Gilead is also expanding existing voluntary licensing agreements for remdesivir to include filovirus disease, contingent on clinical results and potential regulatory approvals. The company has already donated more than 38,000 vials of remdesivir across the Democratic Republic of the Congo, Uganda and Kenya as part of its outbreak-response efforts.

The move strengthens Gilead’s preparedness and global-access strategy for emerging infectious diseases, although neither obeldesivir nor remdesivir is currently approved for Ebola Bundibugyo treatment or prevention.
Post Image
Gilead’s Twice-Yearly Lenacapavir Shows Nearly Double the PrEP Persistence of Daily Oral Therapy

Gilead Sciences (NASDAQ: GILD) reported new Phase 2 data showing that twice-yearly injectable lenacapavir achieved substantially higher one-year persistence than daily oral F/TDF for HIV prevention.

At Week 52, 85.6% of participants receiving lenacapavir remained persistent on PrEP, compared with 46.3% of those taking daily oral F/TDF. The 39.3 percentage-point difference was statistically significant.

No HIV acquisitions occurred among participants receiving lenacapavir during the 52-week study, while one case was reported in the F/TDF group, where drug-level testing indicated very limited adherence.

Safety results were generally consistent with prior lenacapavir studies. Serious adverse events were uncommon, and no participant discontinued lenacapavir because of adverse events, although injection-site reactions were frequent.

The results strengthen Gilead’s case that long-acting HIV prevention could address one of the biggest limitations of daily PrEP: maintaining consistent use over time. The company is also evaluating once-yearly lenacapavir as part of its broader long-acting HIV prevention strategy.
Post Image
Gilead Expands Access Plans for Once-Yearly HIV Prevention Drug

Gilead Sciences (NASDAQ: GILD) is expanding its global access strategy for investigational once-yearly lenacapavir, potentially offering HIV prevention with just one injection per year if the treatment succeeds in clinical trials and receives regulatory approval.

The company expanded six royalty-free voluntary licensing agreements to cover the once-yearly formulation, supporting manufacturing readiness and future supply across 120 high-incidence, primarily low- and lower-middle-income countries. Partners include Dr. Reddy’s, Emcure, Eva Pharma, Ferozsons, Hetero and Viatris subsidiary Mylan.

The drug is currently being evaluated in the Phase 3 PURPOSE 365 study, which is testing whether a single intramuscular dose can maintain HIV-preventive drug concentrations for a full 52 weeks. The once-yearly formulation remains investigational and has not been approved by any regulatory authority.

Lenacapavir is already approved in multiple countries in a twice-yearly formulation for HIV prevention. Extending the dosing interval to once a year could strengthen Gilead’s HIV franchise by reducing the frequency of treatment and potentially addressing adherence and access barriers associated with more frequent PrEP regimens.
Post Image
Gilead and PAHO Partner to Expand Twice-Yearly HIV Prevention Across Latin America

Gilead Sciences (NASDAQ: GILD) and the Pan American Health Organization announced a partnership aimed at expanding access to twice-yearly lenacapavir for HIV prevention across Latin America and the Caribbean. The agreement will use PAHO’s Regional Revolving Funds to support country-led adoption and implementation of the long-acting PrEP treatment.

The agreement creates a new access pathway for 14 countries currently outside Gilead’s voluntary licensing agreements, including Brazil, Mexico, Argentina, Colombia and Chile. It complements existing generic-access programs and could significantly broaden the drug’s regional availability.

Lenacapavir requires only two doses per year and is already approved for HIV prevention in multiple countries. Gilead is also evaluating a once-yearly injectable version as part of its longer-term HIV prevention program.

The partnership represents another step in Gilead’s global commercialization and access strategy for lenacapavir. The company recently expanded its no-profit supply program with PEPFAR and the Global Fund by 50%, targeting access for as many as 3 million people through 2028.
Gilead Wins FDA Approval for Bixlenvo, Expanding Its HIV Treatment Portfolio

Gilead Sciences (NASDAQ: GILD) received U.S. FDA approval for Bixlenvo, a new once-daily single-tablet HIV treatment for virologically suppressed adults, including patients currently requiring complex treatment regimens.

Bixlenvo combines bictegravir, an integrase inhibitor with a high barrier to resistance, with lenacapavir, Gilead’s first-in-class capsid inhibitor. Importantly, it becomes the first and only single-tablet regimen for virologically suppressed patients on complex HIV regimens who cannot use currently available single-tablet options.

Approval was supported by the Phase 3 ARTISTRY-1 and ARTISTRY-2 trials. In both studies, Bixlenvo demonstrated comparable efficacy in maintaining viral suppression through Week 48 and was generally well tolerated, with no significant new safety concerns identified.

The approval is strategically important for Gilead because HIV remains one of its core franchises. Bixlenvo adds a differentiated treatment option for patients with resistance, tolerability issues or complicated multi-pill regimens, while extending the commercial potential of lenacapavir beyond its existing uses. It also strengthens Gilead’s broader strategy of developing daily, weekly and longer-acting HIV treatment and prevention options.
Gilead Stock Slips Despite Strong Core Business Growth as Acquisition Charges Weigh on Earnings

Gilead Sciences (NASDAQ: GILD) shares slipped about 1% on Tuesday despite reporting solid second-quarter revenue growth, as large acquisition-related charges resulted in a quarterly loss.

Second-quarter revenue increased 10% year over year to $7.8 billion, while product sales excluding COVID-19 treatment Veklury rose 10% to $7.6 billion, highlighting continued strength across Gilead's core business. However, the company reported a GAAP loss of $8.45 per share and a non-GAAP loss of $6.75 per share, largely reflecting approximately $9.08 per share of acquired in-process R&D and related tax expenses tied to the acquisitions of Arcellx, Tubulis, and Ouro Medicines.

The HIV franchise remained the company's primary growth engine. HIV product sales increased 12% to $5.7 billion, led by Biktarvy, whose sales rose 7% to $3.8 billion, while Descovy surged 48% as demand and pricing improved. Oncology drug Trodelvy also delivered strong momentum, with sales climbing 26%, and liver disease treatment Livdelzi continued to contribute to growth.

The quarter also included three FDA approvals and three positive Phase 3 clinical updates, further strengthening Gilead's development pipeline. Meanwhile, COVID-19 antiviral Veklury sales fell 81% as pandemic-related hospitalizations continued to normalize, while the cell therapy business faced ongoing competitive pressure.

Looking ahead, Gilead raised its full-year 2026 guidance for product sales excluding Veklury to $29.8 billion-$30.1 billion, reflecting confidence in continued momentum across its HIV and oncology portfolios. The company also expects Veklury sales to decline further to approximately $300 million for the year.

While investors welcomed the strong underlying revenue growth and improving outlook for Gilead's core business, the stock came under modest pressure as the headline earnings figures were heavily impacted by substantial acquisition-related charges associated with expanding the company's long-term pipeline.
Gilead Sciences (GILD) Shares Climb After HSBC Sets $155 Price Target

Gilead Sciences (NASDAQ: GILD) gained 4.2% on Thursday and added another 1.3% in premarket trading on Monday after HSBC initiated coverage on the biopharmaceutical company with a *$155 price target*.

The new price target came as Gilead shares extended their recent rally, reflecting continued investor optimism toward the company's growth prospects across its HIV, oncology, and liver disease portfolios.

The $155 target implies additional upside from Thursday's closing price, suggesting HSBC sees room for further appreciation despite the stock's recent gains. While the rating summary did not disclose the firm's detailed investment thesis, the initiation highlights growing institutional interest in Gilead.

Investor sentiment has also been supported by the company's diversified portfolio, strong cash generation, and continued investment in innovative therapies. Gilead remains focused on expanding its oncology business while maintaining its leadership position in HIV treatments, two areas viewed as key long-term growth drivers.

The combination of Thursday's strong rally and HSBC's new price target kept Gilead in focus as investors continued to favor large-cap pharmaceutical companies with stable earnings and attractive growth opportunities.
# Gilead Edges Lower After Hours as Acquisition Charges Swamp Strong Operating Quarter

Foster City, May 7, 2026 — Shares in Gilead Sciences slipped roughly 1% in after-hours trading yesterday after the biopharmaceutical company reported a solid first quarter operationally but issued full-year EPS guidance that alarmed investors at first glance — a dramatic reduction driven almost entirely by the accounting cost of three major acquisitions rather than any deterioration in the underlying business.

The operating results were genuinely strong. Total revenues grew 4% to $7.0 billion, with base business product sales excluding Veklury up 8% to $6.8 billion. HIV remains the engine, with HIV product sales growing 10% to $5.0 billion. Biktarvy, the company's flagship HIV treatment, rose 7% to $3.4 billion, and Descovy surged 38% to $807 million. Trodelvy, the oncology antibody-drug conjugate, grew 37% to $402 million, reflecting strengthening demand. Non-GAAP diluted EPS improved to $2.03 from $1.81 a year ago, and product gross margin expanded to 87.5% on a non-GAAP basis. Full-year product sales guidance was raised to $30.0 to $30.4 billion from the prior range.

The jolt came from the updated EPS guidance. Full-year non-GAAP diluted EPS was cut to a loss of $0.65 to $1.05, compared to prior guidance of $8.45 to $8.85 — a swing of roughly $9.50 per share. The reason is entirely attributable to $11.5 billion in anticipated acquired in-process R&D charges from the company's acquisition spree: the completed $7.8 billion purchase of Arcellx, the pending acquisition of Ouro Medicines for autoimmune treatments, and the pending Tubulis deal for next-generation antibody-drug conjugates. These are non-cash accounting charges that hit the income statement at closing but represent strategic investments in future pipeline assets rather than operational losses.

Investors familiar with biotech acquisition accounting will recognize the pattern, but the headline EPS reversal is jarring enough to explain the modest after-hours dip as others digest what is actually a strong underlying quarter.
Gilead Sciences announced it has completed its acquisition of Arcellx Inc. in a deal valued at approximately $7.8 billion, strengthening its oncology portfolio.

The transaction gives Gilead full control of anitocabtagene autoleucel (anito-cel), an investigational CAR T-cell therapy for multiple myeloma, allowing the company to streamline development and maximize long-term value by eliminating profit-sharing and royalty obligations.

Gilead said the deal is expected to be dilutive to earnings in 2026 and 2027 but accretive from 2028 onward, subject to regulatory approval of the therapy. Arcellx will now operate as a wholly owned subsidiary of Gilead.

Source: Gilead Sciences press release, Business Wire
Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026

NYSE:DLB

Dolby Falls 3.8% After Hours as Fiscal 2027 Outlook Points to Flat Growth

Dolby Laboratories (NYSE: DLB) shares fell 3.8% after hours despite reporting a strong fiscal fourth quarter, as investors focused on a more muted fiscal 2027 outlook.

Fourth-quarter revenue rose to $374 million from $307 million a year earlier, while non-GAAP EPS increased to $1.25 from $0.99. For the full year, revenue grew 5% to $1.42 billion and non-GAAP EPS increased 3% to $4.36.

Dolby also generated $400 million in operating cash flow, repurchased about $265 million of stock during the year and raised its quarterly dividend to $0.39 per share.

The pressure on the stock appears to reflect guidance for roughly flat fiscal 2027 revenue of about $1.42 billion and non-GAAP EPS of $4.27-$4.42, implying limited earnings growth after a solid fiscal 2026 finish.
Video Thumbnail
11-22-25WS News

UK

Post Image
UK Inflation Holds at 3.6% in October as Producer Input Costs Jump

UK consumer inflation held at 3.6% year over year in October, matching market expectations and edging up from 3.5% previously.

On a monthly basis, CPI rose 0.5%, also in line with consensus and slightly above the prior 0.4% increase.

Producer input prices were notably stronger, rising 2.2% month over month compared with the 0.8% forecast and 1.5% previously.

The data point to persistent inflation pressure, with consumer prices remaining elevated and upstream input costs accelerating more sharply than expected.
Post Image
UK Unemployment Rate Falls to 4.6% as Employment Growth Accelerates

The UK unemployment rate fell to 4.6% in September, below both the 4.7% forecast and the previous 4.7% reading.

Employment increased by 156,000 on a three-month basis, accelerating from the previous gain of 102,000.
Post Image
UK Manufacturing Rebounds in September While Business Investment Slows

UK manufacturing production rose 0.7% month over month in September, beating expectations for a 0.5% decline and matching the previous month’s 0.7% increase.

Industrial production increased 0.3% in September, also outperforming the forecast for a 0.4% contraction, though slowing from the prior 0.7% gain.

Business investment grew 0.4% quarter over quarter in the third quarter, in line with expectations but sharply below the 1.8% increase recorded in the previous quarter.

The data point to stronger-than-expected industrial activity at the end of the third quarter, while the slowdown in business investment suggests a more cautious corporate spending backdrop.
Post Image
UK Economy Grows 0.7% in Q3 as September GDP Rises 0.2%

The UK economy expanded 0.7% quarter over quarter in the third quarter, matching expectations and accelerating from 0.5% growth in the previous quarter.

On an annual basis, GDP increased 1.9% in Q3, also in line with forecasts and up from 1.4% previously.

Monthly GDP rose 0.2% in September, outperforming expectations for no growth and improving from a flat reading in the previous month.

The data point to firmer economic momentum heading into the fourth quarter, with both quarterly and annual growth accelerating and September activity exceeding expectations.
Post Image
UK Retail Sales Growth Edges Up to 1.1% in October

UK retail sales growth improved slightly in October, with the BRC Retail Sales Monitor rising 1.1% year over year.

The reading came in just below the 1.2% forecast but was stronger than the 1.0% increase recorded previously.
Post Image
UK House Prices Fall 0.6% in October, Missing Expectations

UK house prices fell 0.6% month over month in October, significantly weaker than expectations for no change and following a 0.1% decline previously.

On an annual basis, house prices declined 1.2%, compared with the 0.3% contraction forecast and the previous 0.1% decline.

The sharper-than-expected deterioration points to renewed weakness in the UK housing market, suggesting affordability pressures and borrowing costs continue to weigh on demand.
Post Image
Bank of England Holds Rates at 4.00%, Matching Forecast

The Bank of England kept its benchmark interest rate unchanged at 4.00% in November, in line with market expectations.

The decision follows the previous 3.75% rate and therefore represents a 25-basis-point increase from the prior level.
UK Labor Market Strengthens as Employment Jumps and Unemployment Falls

The U.K. labor market showed stronger-than-expected momentum in August, with employment rising sharply and the unemployment rate declining.

Employment increased by 102,000 on a three-month-on-three-month basis, far above the 20,000 consensus estimate and up from the previous increase of 67,000.

The unemployment rate fell to 4.7%, better than the 4.9% forecast and down from 4.9% previously.

The data point to a firmer labor market than economists expected, with stronger hiring and lower unemployment.
UK Economy Grows 0.1% in August as Manufacturing and Industrial Output Beat Expectations

The U.K. economy expanded 0.1% month over month in August, outperforming expectations for a 0.1% contraction, although growth slowed from the previous month’s 0.4% increase.

Manufacturing production rose 1.2% month over month, significantly stronger than the 0.1% decline expected by economists and slightly above the previous month’s 1.0% gain.

Industrial production also surprised to the upside, increasing 0.8% versus expectations for a 0.1% decline and accelerating from 0.3% previously.

The trade deficit narrowed to £18.01 billion, better than the £21.90 billion deficit expected and an improvement from the previous reading shown in the data.

Overall, the figures point to more resilient U.K. economic activity than expected, particularly in manufacturing and industrial production.
Post Image
UK Retail Sales Growth Accelerates to 1.0% in September

UK retail sales increased 1.0% year over year in September, according to the BRC Retail Sales Monitor, exceeding expectations for a 0.8% gain and improving from 0.5% growth in the previous month.

The stronger reading suggests consumer spending gained momentum during September despite continued pressure from elevated borrowing costs and broader cost-of-living concerns.
Video Thumbnail
09-17-26The Investor
Video Thumbnail
08-29-26WS Investor
Video Thumbnail
08-17-26WS Investor
Video Thumbnail
06-22-26WS Investor
Video Thumbnail
04-30-26Global Finance News

NASDAQ:OPRA

Opera Falls 7.3% Despite Strong Q3 Growth and Raised Full-Year Guidance

Opera (NASDAQ: OPRA) shares fell 7.3% despite reporting third-quarter results near the top end of guidance and raising its full-year revenue outlook.

Revenue increased 20% year over year to $182.8 million, while adjusted EBITDA rose 19% to $43.2 million. Operating profit climbed 52% to $34.0 million, and diluted EPS increased to $0.30 from $0.21.

Advertising revenue grew 22% to $116.8 million, query revenue rose 17% to $65.0 million, and annualized ARPU increased 22% to $2.60. Opera also returned $73.3 million to shareholders through repurchases and dividends during the quarter.

Opera raised full-year revenue guidance to $735-$742 million and expects adjusted EBITDA of $172-$175 million. The sharp share decline may therefore reflect elevated expectations or profit-taking rather than an obvious deterioration in the reported operating results.

NYSE:KSS

Post Image
Uber Eats Adds Kohl’s Nationwide for On-Demand Retail Delivery

Uber Technologies (NYSE: UBER) and Kohl’s (NYSE: KSS) launched a nationwide partnership that brings products from more than 1,100 Kohl’s stores onto the Uber Eats marketplace for scheduled or on-demand delivery.

Customers can shop apparel, footwear, home essentials, gifts and participating Sephora at Kohl’s products directly through Uber Eats. The partnership is launching ahead of the holiday season, positioning Uber to capture more last-minute retail demand beyond its traditional restaurant-delivery business.

The agreement expands Uber Eats’ growing retail and commerce offering while giving Kohl’s another digital fulfillment channel across its national store network. Customers can choose products from a nearby Kohl’s location and track delivery through the Uber Eats app.

The partnership is strategically positive for Uber because it broadens marketplace selection and increases the number of non-food use cases on the platform, while Kohl’s gains incremental reach and convenience without building a separate last-mile delivery network.
Bath & Body Works Rises 3.6% as Q2 Beats Guidance and Turnaround Shows Early Progress

Bath & Body Works (NYSE: BBWI) shares rose about 3.6% after the retailer reported fiscal second-quarter 2026 sales and earnings above its guidance and raised its full-year earnings outlook. The positive reaction comes despite continued sales pressure, suggesting investors are focusing on early signs that the company's turnaround strategy is beginning to gain traction.

Q2 Results Beat Expectations

Second-quarter net sales were $1.51 billion, down 2.3% year over year. While revenue remained under pressure, management said the result exceeded its guidance.

Adjusted EPS reached $0.62, compared with $0.37 a year earlier, while adjusted operating income increased to $225 million from $172 million.

However, the headline earnings improvement was heavily influenced by approximately $80 million of tariff refunds. Excluding that benefit, adjusted EPS would have been $0.31.

That distinction is important: the quarter was better than management expected, but the reported year-over-year earnings growth substantially overstates the improvement in the underlying business.

Turnaround Signals Support the Stock

The more encouraging development may be operational rather than purely financial.

Bath & Body Works reported its first quarter of direct net sales growth since 2021, which management attributed partly to improvements in its digital shopping experience. The company also cited sequential improvement in Body Care, stronger average unit retail on new product innovation and continued momentum through marketplace partnerships.

CEO Daniel Heaf said these developments provide early evidence that the company's "Consumer First Formula" strategy is working, although he acknowledged that underlying business trends remain pressured.

For investors, evidence that digital sales and key product categories are stabilizing could be particularly important after an extended period of weak growth.

Full-Year EPS Guidance Raised, But Sales Still Expected to Fall

Bath & Body Works raised fiscal 2026 GAAP EPS guidance to $3.13-$3.33 and adjusted EPS guidance to $2.60-$2.80. The company also expects approximately $650 million of free cash flow.

Sales guidance was narrowed to a decline of 2.5%-4%, indicating that management still expects revenue contraction for the year.

The near-term outlook also remains challenging. For Q3, sales are expected to decline 2.5%-5%, while adjusted EPS of $0.07-$0.12 would be substantially below $0.35 in the year-ago quarter.

The 3.6% rise in BBWI therefore appears to reflect a cautiously positive reaction rather than a clear return to growth. Q2 exceeded guidance, digital sales improved and management raised its earnings outlook, providing evidence that the transformation is making progress. Still, declining sales, weak Q3 earnings guidance and the large contribution from tariff refunds show that the underlying recovery remains at an early stage.
Kohl’s Corporation announced a leadership change effective immediately, appointing Michael Bender as Interim CEO following the termination of former CEO Ashley Buchanan for cause.

The decision came after an investigation found Buchanan had directed vendor transactions involving undisclosed conflicts of interest. His termination is not related to company performance or financial reporting.

Bender, a board member since 2019 and recently appointed Board Chair, brings experience from past executive roles at Eyemart Express, Walmart, L Brands, and PepsiCo. He will step down from his role as Board Chair while serving as Interim CEO. The Board will conduct a formal search for a permanent CEO.

Kohl’s also provided preliminary Q1 2025 financial expectations:
- Comparable sales: down 4.3% to 4.0%
- Operating income: $40 to $45 million
- Diluted EPS: a loss of $0.24 to $0.20

The company will report full Q1 2025 results on May 29, 2025.
Video Thumbnail
08-26-26The Investor
Video Thumbnail
07-23-25WS Investor
Video Thumbnail
05-06-25WS News
Video Thumbnail
05-01-25Global Finance News

NYSE:STT

Post Image
State Street Launches SPDR MyPaycheck ETF for Monthly Income and Inflation Protection

State Street Investment Management has launched the State Street SPDR Nasdaq MyPaycheck ETF (PCHX), a new multi-asset fund designed to provide regular monthly cash flow while maintaining exposure to long-term growth assets.

The ETF tracks the Nasdaq MyPaycheck Total Return Index and targets a diversified allocation of 50% bonds, 25% equities, 20% commodities and 5% real estate. The portfolio is rebalanced monthly and includes inflation-sensitive assets such as TIPS, commodities, gold and real estate.

PCHX is designed to make a fixed-dollar monthly distribution that may be adjusted twice a year for inflation. Distributions can come from portfolio income, realized gains, return of capital or a combination of these sources and are not guaranteed.

The launch broadens State Street’s income-oriented ETF lineup and targets investors seeking a more predictable distribution stream without fully sacrificing growth and inflation protection. The structure could appeal particularly to retirees and other income-focused investors, although the use of return of capital means distributions should not be viewed as equivalent to portfolio yield.
Post Image
State Street Launches SPYMX Mutual Fund Share Class of SPYM for Retirement Plans

State Street Investment Management has launched SPYMX, a new institutional mutual fund share class of the State Street SPDR Portfolio S&P 500 ETF (SPYM), targeting employer-sponsored retirement plans and other eligible institutional investors.

SPYMX provides the same underlying S&P 500 exposure as SPYM but through a mutual fund structure designed to integrate more easily with retirement-plan platforms and recordkeeping systems. Eligible 401(k) and 403(b) plans can access the fund without an investment minimum.

State Street said U.S. large-cap exposure represents about 30% of defined-contribution plan assets nationwide, totaling more than $4 trillion, with roughly half of those assets held in mutual funds. The new structure is intended to combine the operational familiarity of a mutual fund with the scale and liquidity of an existing ETF portfolio.

SPYM has more than $170 billion in assets under management and has tracked the S&P 500 since 2020. The fund was also recently selected as the default investment option for the Trump Accounts program.

The launch expands State Street’s push to bring ETF-style scale and cost efficiency into retirement-plan structures. For plan sponsors, SPYMX offers another low-cost route to broad U.S. large-cap equity exposure without requiring participants to hold the ETF share class directly.
Post Image
State Street Falls 6.4% Despite Strong Q3 Growth as Fee Revenue Slips Sequentially

State Street (NYSE: STT) shares fell about 6.4% after the company reported third-quarter 2026 EPS of $3.69, up 33% year over year, on total revenue of $4.0 billion, up 13%. Net income increased 27% to $1.09 billion, while pre-tax margin expanded to 34.6%.

Assets under custody and administration reached a record $59.2 trillion, up 15%, while assets under management rose 16% to a record $6.3 trillion. State Street also reported $429 billion of new servicing AUC/A wins and $68 million of new servicing fee revenue wins during the quarter.

Revenue growth was broad-based. Servicing fees rose 10% year over year, management fees increased 20%, FX trading services rose 17%, and securities finance increased 9%. Net interest income climbed 21%, supported by a 16-basis-point improvement in net interest margin.

However, there were some softer sequential trends. Total fee revenue declined 2% from the second quarter, while total revenue fell 1% quarter over quarter. FX trading services also declined sequentially despite remaining higher year over year.

Expenses increased 8% year over year, reflecting higher compensation, technology spending and other strategic investments. Information systems and communications expense rose 15%, while compensation and employee benefits increased 8%.

Capital remained solid, with a CET1 ratio of 11.0%. State Street returned $651 million to shareholders during the quarter, including $400 million of share repurchases and $251 million of dividends.

The 6.4% decline appears to reflect investor concern over the sequential decline in fee revenue and total revenue, together with continued expense growth, despite strong year-over-year earnings growth, record AUC/A and AUM, and improved profitability.
State Street Expands MyIncome ETF Suite as Assets Surpass $1 Billion

State Street Investment Management expanded its MyIncome ETF lineup with three new actively managed target-maturity bond ETFs, extending the range across corporate, high-yield and municipal bond exposures.

The new funds are the State Street My2036 Corporate Bond ETF (MYCP), State Street My2032 High Yield Corporate Bond ETF (MYHF) and State Street My2032 Municipal Bond ETF (MYML). The products are designed to help investors build customized bond ladders while managing cash flow, interest-rate exposure and liquidity needs.

The expansion comes as assets in the MyIncome ETF suite surpassed $1 billion. State Street said the suite had $1.16 billion in assets under management as of August 31, 2026.

State Street launched the MyIncome suite in 2024 as the first actively managed corporate and municipal target-maturity bond ETFs in the U.S. market. The firm later added high-yield exposure, and the latest launches extend the maturity range available to investors.

The funds are actively managed with the goal of enhancing income while controlling liquidity, issuer concentration and broader macro risks. They are designed to distribute remaining principal and liquidate around December 15 of their target maturity year.
State Street Corporation announced plans to launch a tokenized fund servicing capability from Luxembourg by the end of 2026, expanding its digital asset infrastructure.

The new service, built on the firm’s Digital Asset Platform, will enable the issuance, administration, and custody of tokenized funds while integrating them with traditional fund structures under a unified operating model. State Street Investment Management is expected to be an early adopter.

The company said Luxembourg was chosen due to its supportive regulatory framework for digital assets, with the initiative aimed at combining traditional and digital fund operations within a consistent governance and risk framework.

Source: State Street press release, Business Wire
State Street Corporation reported a strong start to 2026, posting first-quarter earnings per share of $2.49, or $2.84 excluding notable items, alongside record revenue performance driven by broad-based growth across its businesses. Total revenue rose 16% year-over-year to $3.8 billion, supported by a 15% increase in fee revenue and a 17% rise in net interest income, while net income climbed 19% to $764 million.

The company highlighted significant expansion in its core asset base, with assets under custody and administration (AUC/A) increasing 17% to $54.5 trillion and assets under management (AUM) rising 20% to $5.6 trillion, largely reflecting favorable market conditions and net inflows. Operational momentum was also evident in new business wins, including $56 million in servicing fee revenue and $365 billion in new AUC/A mandates during the quarter.

Growth was broad across segments, with management fees up 23%, foreign exchange trading revenue rising 29%, and servicing fees increasing 11%. The firm also reported record FX trading volumes and continued gains in ETF inflows and software-related revenues. Despite a 15% increase in expenses—partly due to restructuring and investment costs—State Street maintained solid profitability, delivering a pre-tax margin of 25.5% and positive operating leverage.

CEO Ron O’Hanley emphasized the company’s resilience and diversified model, noting that continued strategic execution and client-focused operations drove the strong quarterly performance, while acknowledging ongoing macroeconomic and geopolitical uncertainties.
State Street announced it will support Dimensional Fund Advisors’ rollout of ETF share classes for U.S. mutual funds, marking the first implementation of this structure under new SEC rules.

Dimensional becomes the first U.S. asset manager to introduce ETF share classes within actively managed mutual funds, a development expected to enhance tax efficiency and reduce costs for investors.

State Street will provide full-service support, including custody, fund accounting, ETF operations, and reporting, leveraging its global ETF servicing capabilities to enable the launch.
Business Wire
State Street Corporation (NYSE: STT) is going to announce its first-quarter 2026 financial results on Friday, April 17, 2026 at 7:30 a.m. ET. A conference call will be held at 11:00 a.m. ET.
State Street Investment Management launched the State Street IG Public & Private ABS ETF (PRAB), an actively managed exchange-traded fund designed to give investors broader exposure to investment-grade asset-backed securities across both public and private markets.

The fund invests in securities such as collateralized loan obligations (CLOs) and residential and commercial mortgage-backed securities, aiming to provide diversified income opportunities and potentially higher yields compared with corporate bonds of similar risk.

State Street said the ETF responds to growing investor demand for access to the global asset-backed finance market, which exceeds $20 trillion but remains underrepresented in traditional bond portfolios.
Business Wire
State Street Investment Management has expanded its MyIncome ETF lineup with the launch of five actively managed high yield corporate bond target maturity ETFs, adding to what it calls the industry’s first actively managed corporate target maturity ETF suite.

The new funds — My2027 (MYHA), My2028 (MYHB), My2029 (MYHC), My2030 (MYHD) and My2031 (MYHE) High Yield Corporate Bond ETFs — provide exposure to high yield bonds with matching maturity years from 2027 through 2031. The ETFs are designed to help investors build bond ladders that manage interest rate risk while offering predictable income and liquidity.

Managed by the firm’s fixed income team, the funds aim to maximize yield while preserving capital and managing liquidity, sector and issuer concentration risks. Each ETF is structured to distribute remaining principal and liquidate around December 15 of its respective maturity year. As of January 31, 2026, assets under management in the MyIncome suite totaled $298 million.

Source:Business Wire